HEALTH

Lunsotogene Parvec Becomes First FDA-Approved Gene Therapy for OTOF-Related Hearing Loss

From AJMC · April 23, 2026 · Curated by DeafMonitor

DeafMonitor aggregates Deaf-community news and credits every story to its original publisher. This story was reported by AJMC.
Read the full story at AJMC

Open in the live feed Browse all stories

More Health stories

My Mother's Spices June 12, 2026
Delhi woman with severe hearing loss secures new milestone after cochlear implant surgery June 12, 2026
Ireland’s life-changing cochlear implant story June 12, 2026
Maharashtra Gets In-Principle Centre Nod To Extend Cochlear Implant Eligibility Age To 5 Years Under RBSK June 12, 2026
Targeting mitochondria to protect against noise-induced hearing loss June 12, 2026
Developing gene therapy for TOMT-linked hearing loss June 12, 2026